De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
BioNTech Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
BioNTech heeft een totaal eigen vermogen van €19.1B en een totale schuld van €0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk €22.2B en €3.2B.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
€0
Schuld
| Rente dekkingsratio | n/a |
| Contant | €17.30b |
| Aandelen | €19.07b |
| Totaal verplichtingen | €3.17b |
| Totaal activa | €22.24b |
Recente financiële gezondheidsupdates
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05Recent updates
BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth
Sep 13BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Aug 20BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Aug 06Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( €18.3B ) BNTX } overtreffen de korte termijn passiva ( €2.4B ).
Langlopende schulden: De kortetermijnactiva BNTX ( €18.3B ) overtreffen de langetermijnschulden ( €739.7M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: BNTX is schuldenvrij.
Schuld verminderen: BNTX heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 3% was.
Schuldendekking: BNTX heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.
Rentedekking: BNTX heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.